Ozempic (semaglutide)
- A GLP-1 receptor agonist FDA-approved to treat type 2 diabetes.
- The same ingredient, sold as Wegovy, is approved for chronic weight management.
- In clinical trials, Wegovy users lost an average of about 15% of body weight over 68 weeks.
- Common side effects include nausea, vomiting and diarrhea.
